AC Immune

Today, we are excited to report favorable interim safety data from our Phase 1b/2 ABATE trial in Down syndrome. Our anti-Abeta active immunotherapy, ACI-24.060, was generally safe and well tolerated in individuals living with Down syndrome. After treatment for up to one year, there have been no serious adverse events related to the study drug and no case of amyloid-related imaging abnormalities (ARIA) observed in this population. Based upon these findings, the trial will now start to evaluate the high dose of ACI-24.060 in additional individuals living with Down syndrome and recruitment continues at ABATE trial sites in the U.S., U.K., and Spain. Read the full PR here: https://lnkd.in/emEYGNCE ACI-24.060 is an investigational candidate and currently undergoing clinical trials to evaluate its safety and efficacy. It is not yet approved for commercial use and its use is restricted within the context of ongoing clinical studies. ABATE ClinicalTrials.gov Identifier: NCT05462106 To learn more about ABATE visit the study website: https://lnkd.in/eJH9z7Qe #Alzheimers #immunotherapy #precisionmedicine #prevention #DownSyndrome

Movember at AC Immune: Running for a cause! Our colleagues at AC Immune came together to organize a #Movember FUNdraising run. Movember is about raising awareness and funds for men’s health — tackling issues like mental health, suicide prevention, prostate cancer and testicular cancer. Whether it’s growing a moustache, running in style or cheering from the sidelines, every effort counts! Thank you to everyone who joined the run or supported this important initiative. Together, we’re growing stronger (and maybe a little hairier) to make an impact! #MensHealth #StrongerTogether

AC Immune is honored to be among the finalists for Deal of the Year at the prestigious Scrip Awards 2024 for our exclusive, worldwide option and license agreement with Takeda, covering ACI-24.060 and other active immunotherapies targeting amyloid beta. Our collaboration with Takeda is forging a new path to address significant unmet needs in neurodegenerative diseases and advance innovative solutions for Alzheimer’s. The Scrip Deal of the Year Award recognizes agreements that deliver outstanding value, including accelerating innovative therapies to market, replenishing pharmaceutical pipelines, and generating significant benefits for partners and stakeholders. We congratulate the other finalists: AstraZeneca Fusion Pharmaceuticals Gracell Biotechnologies Daiichi Sankyo US Merck Group Intas Pharmaceuticals Henlius Johnson & Johnson Protagonist Therapeutics Sanofi and Teva Pharmaceuticals. #ScripAwards2024 #DealOfTheYear #Alzheimers #Innovation #Partnership #PrecisionMedicine 

“I am so convinced that we will finally be treating #Alzheimer’s. We will eliminate it from the world by actually preventing it,” Andrea Pfeifer said in this BiotechTV interview with Amy Brown. Pathological proteins in the brain that underlie neurodegenerative diseases are the key therapeutic targets for investigational active immunotherapies for the emerging field of precision prevention. This was exemplified by recent encouraging Phase 2 interim results on ACI-7104.056, wholly-owned active immunotherapy targeting alpha-synuclein, in people with early Parkinson’s disease. Andrea and Amy also reviewed the most recent Phase 2 clinical data and upcoming milestones for active immunotherapies against Abeta and Tau, partnered with Takeda and Janssen Inc., respectively. Click here for the full interview https://lnkd.in/e7AGNMTn #Biotech #Alzheimers #PrecisionMedicine #PharmaPartnership #Neurodegeneration 

We are thrilled to announce that AC Immune and Takeda have won the #Deal of the Year (>€500M) at the European Lifestars Awards - Celebrating Life Science Leaders. This recognition highlights our transformative license and option agreement centered on ACI-24.060, our active immunotherapy candidate targeting toxic forms of amyloid beta in Alzheimer’s disease. Currently under evaluation in the ABATE Phase 1b/2 trial, ACI-24.060 has also received Fast Track designation from the U.S. FDA, emphasizing its potential to address this critical unmet medical need. This #partnership with Takeda embodies our commitment to pioneering precision prevention for neurodegenerative diseases. Thank you to our dedicated team at AC Immune and our partners at Takeda for making this possible. Together, we will reshape the future of #Alzheimer’s #treatment and #prevention. #Neurodegeneration #PrecisionMedicine #Award #Biotech #Biopharma

We are pleased to announce positive interim safety and immunogenicity data from our Phase 2 VacSYn trial evaluating ACI-7104.056, our wholly owned anti-alpha-synuclein active #immunotherapy, for the treatment of patients with early Parkinson’s disease. Three immunizations of ACI-7104.056 induced an immune response increasing antibody levels 16-fold on average compared to placebo background, with no clinically relevant safety issues reported to date. These promising clinical results bring us closer to effective prevention strategies in Parkinson's disease, and we look forward to reporting pharmacodynamic data and the decision to expand into Part 2 of the VacSyn study in H1 2025. Read the full PR here: https://lnkd.in/eUyuXnsy #Parkinsons #Prevention #ActiveImmunotherapy #ClinicalData

Join AC Immune’s Management Team for a fireside chat at the #Jefferies London #Healthcare #Conference 2024 to get the latest updates on our clinical-stage active immunotherapy pipeline for neurodegenerative diseases. Follow this link to the webcast: https://lnkd.in/eM_KJikn #Alzheimers #Prevention  #ActiveImmunotherapy #JefferiesHealthcare #Conference

Today, AC Immune reported Q3 2024 financial results and provided a corporate update. Read the full press release here: https://lnkd.in/ePUVpTDv #financialresults #alzheimers #parkinsons #prevention #precisionmedicine

Join us at the Symposium on Parkinson’s disease and related disorders! This event will bring together patients and experts from a variety of institutions and associations to share the latest advances in fundamental research, clinical applications and patient care. When: October 25, 2024 Where: EPFL, Building SG, Lausanne Time: 8:30 AM - 4:30 PM Whether you're a patient, caregiver, researcher or healthcare professional, register online by October 20 to connect and collaborate on Parkinson’s research. #Parkinsons #Research #Healthcare #PatientCare #EPFL #PrecisionMedicine

Each October, we mark #DownSyndromeAwarenessMonth – an opportunity to raise awareness of challenges faced by people with #DownSyndrome (DS). It’s important to recognize that people with DS are not only capable of participating in research, but also want to be included. AC Immune is one of the few companies to include people with DS in trials of #Alzheimer’s disease (AD) therapies. This is particularly important because people with DS often get AD when they get older, but they are rarely taken into consideration in clinical development of new therapies – as our CEO Andrea Pfeifer and Michael S. Rafii, MD, PhD recently outlined in an article in Clinical Leader magazine. Our ABATE study is testing an active immunotherapy candidate, ACI-24.060, that teaches the body’s immune system to target pathogenic forms of the beta amyloid protein in the brain, which could potentially delay or prevent the onset of AD. Our experience shows that with advice and support from patients, advocacy groups, caregivers, and KOLs, it is absolutely possible to design studies that are adapted to the unique needs of individuals with DS. Click here for the full article in Clinical Leader https://lnkd.in/ecF3rQqv And here for more on the ABATE Study https://lnkd.in/eudF-VpA #PrecisionMedicine #Neuroscience #Neurodegeneration